Biolyst › KURAKura Oncology, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on October 20, 2026, a projected date rather than a confirmed one. There are 7 upcoming events on record.
Cash runway is approximately 18.1 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 9 concluded trials, 56% reached completion rather than being terminated or withdrawn.
Upcoming catalysts
Date Event Type Phase
October 20, 2026 est.
Next quarterly earnings (projected) Earnings
—
December 15, 2026
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia Trial Milestone
Phase 1
January 15, 2027
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors Trial Milestone
Phase 1
December 15, 2027
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Trial Milestone
Phase 1
October 16, 2028
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Trial Milestone
Phase 1/Phase 2
April 15, 2030
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML Trial Milestone
Phase 1
November 15, 2031
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML Trial Milestone
Phase 3
Track KURA alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open KURA in the tracker
Recent history
Date Event Type Phase
September 9, 2026
8-K filed: Other event Filing
—
September 8, 2026
8-K filed: Leadership change Corporate
—
August 12, 2026
Quarterly results filed (8-K) Earnings
—
July 29, 2026
8-K filed: Leadership change Corporate
—
June 4, 2026
8-K filed: Leadership change Corporate
—
May 12, 2026
Quarterly results filed (8-K) Earnings
—
March 5, 2026
Quarterly results filed (8-K) Earnings
—
January 12, 2026
Quarterly results filed (8-K) Earnings
—
December 2, 2025
8-K filed: Other event Filing
—
November 13, 2025
8-K filed: Other event Filing
—
November 4, 2025
Quarterly results filed (8-K) Earnings
—
October 24, 2025
8-K filed: Other event Filing
—
October 16, 2025
8-K filed: Other event Filing
—
August 29, 2025
Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Trial Milestone
Phase 1/Phase 2
August 7, 2025
Quarterly results filed (8-K) Earnings
—
July 1, 2025
8-K filed: Material agreement Corporate
—
June 18, 2025
8-K filed: Other event Filing
—
June 6, 2025
8-K filed: Leadership change Corporate
—
June 3, 2025
8-K filed: Other event Filing
—
May 1, 2025
Quarterly results filed (8-K) Earnings
—
May 2, 2023
Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy Trial Milestone
Phase 2
May 2, 2023
Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies Trial Milestone
Phase 1
March 31, 2021
Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy Trial Milestone
Phase 2
December 14, 2020
Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations Trial Milestone
Phase 2
November 30, 2020
Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia Trial Milestone
Phase 2
June 2, 2020
First-in-Human Study of KO-947 in Non-Hematological Malignancies Trial Milestone
Phase 1
August 28, 2018
Tipifarnib in Subjects With Myelodysplastic Syndromes Trial Milestone
Phase 2
About this data
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.